The p53 protein is crucial for cancer development and progression. p53 is mutated in nearly 50% of all human cancers, is functionally inactivated in an additional 20% of cases, and human as well as mice without p53 show a dramatic increase in cancer incidence. Dr. Arnold Levine has been at the forefront of p53 research since the discovery of this tumor suppressor. It is therefore a privilege to have his personal view on this field.
While at a meeting in Montalcino in Tuscany, Italy, Dr. Scott Lowe agreed to discuss his findings on p53 transcriptional activity. In particular, Scott discusses the role of senescence and how the different pathways elicited by p53 can balance and integrate the function of this powerful transcription factor in suppressing cancer. His insightful views challenge the field about what they will face in the near future.
The involvement of Dr. Doug Green in p53 research arose from observations made a decade earlier by Moshe Oren. This then led Doug's laboratory to identify a non-transcriptional function of this DNA binding protein influencing mitochondria directly and cell death. Green was interviewed at Waikiki beach in Honolulu, Hawaii.
The main theme of Dr. Henning Walczak's research focuses on death receptor proteins. Walczak's team has been interested in how these important regulators of cell death synergize with p53. Indeed he discusses, in Montalcino in Tuscany, Italy, the interaction of TRAIL and CD95 with p53 to affect cancer cells.
Video Series on Autophagy
Video summary of the Special issue on Dying Cell Recognition published June 2016. See the full Special Issue here: http://www.nature.com/cdd/journal/v23/n6/index.html
Dr Jennifer Martinez discusses how her team examine efferocytosis and the impact of LAP on efferocytosis, allowing us to reimagine the impact of the autophagy machinery on innate host defense mechanisms. See the full article here: http://www.nature.com/cdd/journal/v23/n6/abs/cdd2015172a.html